Explore 3 Stock Ideas & Industry Insights Download Free Report

Scpharmaceuticals Inc

Company price
None USD 0.00(0%)
Last update at 2025-11-06T20:10:50.352480Z
Market Cap
137.19M

Momentum Score

…

scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX. The company's product pipeline also includes SCP-111 (furosemide injection), an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home; and SCP-111 Autoinjector, an investigational single-entity, drug-device combination product candidate consisting of a prefilled syringe containing SCP-111, preloaded into a commercially available, fixed single dose, disposable, two step mechanical autoinjector. It has a collaboration agreement with West Pharmaceutical Services, Inc. The company was incorporated in 2013 and is headquartered in Burlington, Massachusetts.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
3.24
Low
11.75
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
-
Dividend Yield
-
Revenue TTM
17.63M
Revenue Per Share
0.45
Gross Profit TTM
0.00M
Debt / Equity
1.08
ROE
-114.99%
Net Debt
-6.54M
ROCE
-44.45%
Diluted EPS TTM
-1.48

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -36.84M -28.03M -32.21M -33.00M -29.44M
Net income -37.52M -30.49M -34.39M -34.41M -29.44M
Selling general administrative 20.62M 9.78M 11.78M 8.27M 13.72M
Gross profit - - - - 0.00M
Reconciled depreciation 0.47M 0.44M 0.40M 0.36M 0.33M
Ebit -36.16M -25.82M -29.93M -32.91M -28.34M
Ebitda -33.54M -25.46M -29.62M -31.23M -28.01M
Depreciation and amortization 2.62M 0.36M 0.31M 1.68M 0.33M
Non operating income net other 2.62M 0.36M 0.31M 1.68M 1.66M
Operating income -36.16M -25.82M -29.93M -32.91M -29.67M
Other operating expenses 36.16M 25.82M 29.93M 32.91M 29.67M
Interest expense 3.30M 2.58M 2.59M 1.77M 1.43M
Interest income 1.20M 0.05M 0.32M 1.66M 1.71M
Net interest income -2.10M -2.53M -2.27M -0.11M 0.28M
Income tax expense 0.68M 2.45M 2.18M 1.42M -0.22M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 36.16M 25.82M 29.93M 32.91M 29.67M
Cost of revenue - - - - 0.00M
Total other income expense net -0.68M -2.21M -2.28M -0.09M -0.06M
Net income from continuing ops -36.84M -28.03M -32.21M -33.00M -29.44M
Net income applicable to common shares -36.84M -28.03M -32.21M -33.00M -29.44M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 94.48M 124.19M 79.04M 109.05M 77.28M
Other current assets 3.60M 1.43M 0.02M 0.12M 0.09M
Total liab 57.26M 51.76M 22.57M 26.88M 25.92M
Total stockholder equity 37.22M -226.54M -189.70M -161.66M -129.46M
Deferred long term liab - 7.52M - - 0.77M
Other current liab 8.96M 5.33M 0.03M 4.79M 3.69M
Common stock 0.00M 0.00M 0.00M 0.00M 0.00M
Capital stock 0.00M 0.00M 0.00M 0.00M 0.00M
Retained earnings -281.35M -226.54M -189.70M -161.66M -129.46M
Other liab - 7.54M 0.37M 0.22M 0.06M
Other assets 0.00M 0.27M 0.28M 1.13M 0.33M
Cash 46.81M 71.06M 74.27M 105.28M 72.81M
Total current liabilities 13.13M 7.42M 14.85M 9.32M 5.24M
Current deferred revenue - - 4.00M - -
Net debt -6.54M -33.69M -56.63M -85.07M -52.54M
Short term debt 0.18M 0.57M 10.28M 2.87M 0.41M
Short long term debt - - 9.80M 2.41M -
Short long term debt total 40.27M 37.37M 17.64M 20.21M 20.27M
Other stockholder equity 318.56M -0.04M -0.00M -0.00M -0.00M
Property plant equipment - 0.05M 0.07M 0.91M 1.31M
Total current assets 92.94M 123.31M 78.28M 107.83M 75.65M
Net tangible assets - 72.43M 63.11M 82.17M 51.37M
Short term investments 29.20M 47.12M 1.01M 33.28M -
Net receivables 4.49M 2.28M - - 0.31M
Long term debt 38.81M 36.79M 7.35M 16.86M 18.91M
Inventory 8.84M 1.23M - - 2.44M
Accounts payable 4.00M 1.52M 0.54M 1.67M 1.14M
Accumulated other comprehensive income -0.00M 0.03M -0.00M 0.00M -0.10M
Common stock total equity - 0.00M 0.00M 0.00M 0.00M
Retained earnings total equity - -226.54M -189.70M -161.66M -129.46M
Non currrent assets other 0.08M 0.27M 0.28M 0.31M 0.33M
Non current assets total 1.54M 0.89M 0.76M 1.22M 1.64M
Capital lease obligations 1.46M 0.57M 0.48M 0.94M 1.35M
Long term debt total - 36.79M 7.35M 16.86M 18.91M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -45.84M 32.14M -33.46M -33.46M -33.46M
Change to liabilities 1.77M -2.37M 1.21M 0.96M -1.38M
Total cashflows from investing activities -45.86M 32.13M -33.46M -33.46M -33.46M
Net borrowings 29.80M -2.50M -2.50M 9.55M -0.06M
Total cash from financing activities 77.23M -2.53M 60.35M 13.59M -0.01M
Change to operating activities -0.89M -0.23M 0.24M -0.61M -0.83M
Net income -36.84M -28.03M -32.21M -33.00M -29.44M
Change in cash -3.21M 2.45M -0.81M -16.85M -28.82M
Begin period cash flow 74.45M 72.00M 72.81M 89.66M 118.48M
End period cash flow 71.24M 74.45M 72.00M 72.81M 89.66M
Total cash from operating activities -34.58M -27.15M -27.69M -30.44M -28.81M
Issuance of capital stock 47.77M 0.00M 60.58M 3.97M 0.00M
Depreciation 0.47M 0.44M 0.40M 0.36M 0.33M
Change to inventory -1.23M -1.23M -1.23M -1.23M -
Sale purchase of stock 1.34M -0.08M -0.16M 4.03M -0.00M
Other cashflows from financing activities 46.96M 0.05M -0.06M 9.62M 0.06M
Change to netincome 3.72M 2.92M 2.67M 1.83M 2.51M
Capital expenditures 0.02M 0.01M 0.01M 0.01M 0.01M
Cash flows other operating -1.79M -0.23M 0.27M -0.61M -0.83M
Cash and cash equivalents changes -3.21M 2.45M -0.81M -16.85M -28.82M
Change in working capital -0.35M -2.60M 1.45M 0.35M -2.21M
Stock based compensation 2.84M 2.37M 2.00M 1.45M 2.13M
Other non cash items -0.69M 0.68M 0.64M 0.39M 0.37M
Free cash flow -34.60M -27.16M -27.69M -30.44M -28.81M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
NVO
Novo Nordisk A/S
-1.06
2.73%
37.81 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc
-5.64
1.08%
515.02 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc
-
-%
920.69 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE
-
-%
965.00 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Scpharmaceuticals Inc

scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX. The company's product pipeline also includes SCP-111 (furosemide injection), an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home; and SCP-111 Autoinjector, an investigational single-entity, drug-device combination product candidate consisting of a prefilled syringe containing SCP-111, preloaded into a commercially available, fixed single dose, disposable, two step mechanical autoinjector. It has a collaboration agreement with West Pharmaceutical Services, Inc. The company was incorporated in 2013 and is headquartered in Burlington, Massachusetts.

25 Mall Road, Burlington, MA, United States, 01803

617 517 0730

135

Name Title Year Born
Mr. John H. Tucker Pres, CEO, Principal Exec. Officer, Principal Financial Officer & Director 1963
Ms. Rachael Nokes Sr. VP of Fin. & Principal Accounting Officer 1975
Katherine Taudvin Director of Corp. Devel. & Investor Relations NA
Dr. John Mohr Pharm.D. Sr. VP of Clinical Devel. & Medical Affairs NA
Mr. Michael D. Hassman Sr. VP of Technical Operations NA
Mr. John H. Tucker President, CEO, Principal Executive Officer & Director 1963
Ms. Rachael Nokes CFO & Principal Accounting Officer 1976
Mr. Michael D. Hassman Senior Vice President of Technical Operations NA
Katherine Taudvin Vice President of Corporate Affairs & Human Resources NA
Dr. John Mohr Pharm.D. Senior Vice President of Clinical Development & Medical Affairs NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…